TRIPS Agreement (1994) — Treaty Brief

Overview

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), concluded in 1994 as part of the World Trade Organization (WTO) framework, establishes minimum standards for the protection and enforcement of intellectual property (IP) rights among member states. It aims to harmonize IP laws globally to reduce trade distortions and promote innovation and technology transfer. TRIPS covers a broad range of IP categories including copyrights, trademarks, patents, geographical indications, industrial designs, and trade secrets. By linking IP protection with international trade rules, the treaty incentivizes innovation while seeking to balance the interests of rights holders and public welfare, notably in areas like public health.

Key obligations

• Minimum standards of protection: States must provide legal protections for various IP rights, including patents (20 years minimum term, Article 33), copyrights, trademarks, and geographical indications, consistent with TRIPS provisions.
• Enforcement measures: Members are required to establish effective enforcement mechanisms, both civil and criminal, to deter IP infringement (Articles 41-61).
• National treatment and most-favored-nation (MFN) principle: Foreign IP holders must receive treatment no less favorable than nationals (Article 3) and MFN treatment (Article 4).
• Patentability criteria: Patents must be available for inventions in all fields of technology, subject to exceptions (Article 27).
• Compulsory licensing: Members may grant compulsory licenses under certain conditions, such as public health emergencies, but must follow procedural safeguards (Article 31).
• Transitional arrangements: Developing and least-developed countries (LDCs) were given extended deadlines to implement TRIPS obligations (Article 65).
• Dispute settlement: TRIPS disputes are subject to WTO’s dispute settlement mechanism (Article 64).

Signatories and status

TRIPS is a WTO agreement, meaning all WTO members are bound by it. Major signatories include the United States, European Union member states, China, Japan, India, Brazil, and South Africa. The agreement’s universality is notable because it links IP protection to trade membership, effectively making it a global standard. Some countries outside the WTO framework are not bound by TRIPS, but these are exceptions. Among WTO members, there is variation in compliance and implementation, especially between developed countries and developing or least-developed countries, which have been granted transitional periods. No major WTO member has formally withdrawn from TRIPS, though some have sought waivers or flexibilities.

Major controversies

• Access to medicines and public health: Perhaps the most contentious issue has been the balance between patent protection and access to affordable medicines. Developing countries and NGOs have criticized TRIPS for limiting their ability to produce or import generic drugs, especially for HIV/AIDS, tuberculosis, and malaria. The 2001 Doha Declaration reaffirmed the right of WTO members to use TRIPS flexibilities, such as compulsory licensing, to protect public health.
• Interpretation of compulsory licensing: Disputes have arisen over the scope and conditions under which compulsory licenses can be issued (Article 31), with some developed countries pushing for stricter interpretations.
• Enforcement disparities: Enforcement of IP rights varies widely, with some developing countries lacking capacity or political will to fully implement TRIPS standards, leading to concerns about “TRIPS-plus” provisions in bilateral trade agreements that go beyond TRIPS requirements.
• Geographical indications: Disputes exist over the protection of geographical indications, particularly between the EU and countries like the US, where the scope and enforcement differ.
• Technology transfer: Critics argue that TRIPS has not sufficiently promoted technology transfer to developing countries as originally intended (Article 66.2).

Recent developments

In the past five years, notable developments include ongoing debates over TRIPS waivers related to COVID-19 vaccines and treatments. In 2020-2022, several developing countries proposed temporary waivers on certain TRIPS provisions to facilitate wider access to COVID-19 technologies. Although a WTO decision in 2022 allowed some limited waivers, it fell short of the broad waiver many had sought, highlighting persistent tensions between IP protection and global public health needs. Additionally, discussions continue on digital technologies and IP, including enforcement challenges related to online piracy and emerging technologies like artificial intelligence, though no formal amendments to TRIPS have been adopted.

Why it matters now

TRIPS remains central to the global governance of intellectual property, shaping innovation incentives and access to knowledge worldwide. Its role in balancing IP protection with public health, especially amid pandemics and technological change, makes it a critical framework for policymakers, negotiators, and advocates engaged in international trade, development, and health diplomacy. Understanding TRIPS is essential for navigating contemporary debates on equitable access to technology and the future of global IP norms.